Biolase Wins New FDA Waterlase Approval
SAN CLEMENTE, Calif., July 16 -- Biolase Technology Inc. has received further clearance from the US Food and Drug Administration to market its Waterlase dental laser for additional soft tissue procedures. These procedures include sulcular debridement and implant recovery.
Sulcular debridement is the removal of diseased tissue in the treatment of periodontal disease. Periodontal (gum) disease is the number-one oral health problem, with three out of four adults needing treatment for periodontal disease at some time in their lives, according to the American Dental Association.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024